-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Industry News] According to incomplete statistics, on April 19, a total of 49 listed companies disclosed their performance in the first quarter of 2022, of which 5 were pharmaceutical companies, including Keqian Bio, Chengda Pharmaceutical, Xiangsheng Medical, Xinlitai , Shengxiang Biological,
etc.
Keqian Bio: Both revenue and net profit dropped in the first quarter of 2022, according to the company's revenue and net profit in the first quarter of this year
.
Among them, the operating income was 203 million yuan, a year-on-year decrease of 36.
46%; the net profit was 90.
766 million yuan, a year-on-year decrease of 46.
28%
.
As for the reasons for the changes in performance, Keqian Bio said that it was mainly affected by the market environment.
The decrease in farmers' willingness to purchase vaccines led to a decrease in operating income, and the decrease in operating income led to a decrease in profits
.
According to the data, Keqian Bio is a biopharmaceutical enterprise focusing on the research and development, production, sales and animal epidemic prevention technical services of veterinary biological products.
The main products are non-state compulsory immunization pig vaccines and poultry vaccines
.
At present, the company can produce 49 veterinary biological products
.
Chengda Pharmaceutical: Net profit increased by 25.
28% year-on-year According to the first quarter report of 2022 released by Chengda Pharmaceutical, during the reporting period, the company achieved operating income of 109 million yuan, a year-on-year increase of 23.
54%; realized net profit attributable to shareholders of listed companies 26.
2299 million yuan, a year-on-year increase of 25.
28%
.
According to the data, Chengda Pharmaceutical's main business is: mainly committed to providing key pharmaceutical intermediate CDMO services for multinational pharmaceutical companies and pharmaceutical R&D institutions, and engaged in the research and development, production and sales of L-carnitine series products
.
Xiangsheng Medical: Net profit increased by 9.
05% year-on-year According to the performance report of Xiangsheng Medical for the first quarter of 2022, from January 1, 2022 to March 31, 2022, the company achieved an operating income of 100 million yuan, a year-on-year increase of 23.
04%, and a net profit of 24.
852 million Yuan, an increase of 9.
05% year-on-year, and basic earnings per share was 0.
31 yuan
.
According to the data, Xiangsheng Medical's main business is the research and development, manufacturing and sales of ultrasonic medical imaging equipment
.
Since its establishment, the company has always adhered to the technical concept of independent research and development, and adhered to the development strategy of localization of ultrasound medical imaging technology.
The strategy of simultaneously developing the market, and establishing strategic cooperative relations with internationally renowned medical device companies such as Canon, AstraZeneca, and Bard, the company's products are well recognized by the market
.
Xinlitai: Net profit increased by 53.
09% year-on-year According to Xinlitai's 2022 first quarter results announcement, the company's revenue in the first quarter of 2022 was about 935 million yuan, a year-on-year increase of 22.
11%; net profit was about 237 million yuan, a year-on-year increase of 53.
09% ; Basic earnings per share was 0.
22 yuan, a year-on-year increase of 46.
67%
.
According to the data, the main business of Xinlitai’s subsidiaries involves the research and development, production and sales of drugs and medical device products.
The main products and research projects include cardiovascular drugs and medical devices, cephalosporin antibiotics and raw materials, orthopedic drugs, etc.
Covering cardiovascular and cerebrovascular, hypoglycemic, orthopedics, anti-tumor, anti-infection and other therapeutic fields
.
Shengxiang Bio: Net profit increased by 4.
78% year-on-year.
Shengxiang Bio's performance report for the first quarter of 2022 shows that from January 1, 2022 to March 31, 2022, the company achieved operating income of 1.
44 billion yuan, a year-on-year increase of 23.
81%; net profit; 652 million yuan, a year-on-year increase of 4.
78%; basic earnings per share were 1.
65 yuan
.
The company belongs to the medical device industry, and its main business is an overall solution for in vitro diagnostics that integrates the R&D, production, and sales of diagnostic reagents and instruments, as well as third-party medical testing services, with independent innovative genetic technology as the core
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
etc.
Keqian Bio: Both revenue and net profit dropped in the first quarter of 2022, according to the company's revenue and net profit in the first quarter of this year
.
Among them, the operating income was 203 million yuan, a year-on-year decrease of 36.
46%; the net profit was 90.
766 million yuan, a year-on-year decrease of 46.
28%
.
As for the reasons for the changes in performance, Keqian Bio said that it was mainly affected by the market environment.
The decrease in farmers' willingness to purchase vaccines led to a decrease in operating income, and the decrease in operating income led to a decrease in profits
.
According to the data, Keqian Bio is a biopharmaceutical enterprise focusing on the research and development, production, sales and animal epidemic prevention technical services of veterinary biological products.
The main products are non-state compulsory immunization pig vaccines and poultry vaccines
.
At present, the company can produce 49 veterinary biological products
.
Chengda Pharmaceutical: Net profit increased by 25.
28% year-on-year According to the first quarter report of 2022 released by Chengda Pharmaceutical, during the reporting period, the company achieved operating income of 109 million yuan, a year-on-year increase of 23.
54%; realized net profit attributable to shareholders of listed companies 26.
2299 million yuan, a year-on-year increase of 25.
28%
.
According to the data, Chengda Pharmaceutical's main business is: mainly committed to providing key pharmaceutical intermediate CDMO services for multinational pharmaceutical companies and pharmaceutical R&D institutions, and engaged in the research and development, production and sales of L-carnitine series products
.
Xiangsheng Medical: Net profit increased by 9.
05% year-on-year According to the performance report of Xiangsheng Medical for the first quarter of 2022, from January 1, 2022 to March 31, 2022, the company achieved an operating income of 100 million yuan, a year-on-year increase of 23.
04%, and a net profit of 24.
852 million Yuan, an increase of 9.
05% year-on-year, and basic earnings per share was 0.
31 yuan
.
According to the data, Xiangsheng Medical's main business is the research and development, manufacturing and sales of ultrasonic medical imaging equipment
.
Since its establishment, the company has always adhered to the technical concept of independent research and development, and adhered to the development strategy of localization of ultrasound medical imaging technology.
The strategy of simultaneously developing the market, and establishing strategic cooperative relations with internationally renowned medical device companies such as Canon, AstraZeneca, and Bard, the company's products are well recognized by the market
.
Xinlitai: Net profit increased by 53.
09% year-on-year According to Xinlitai's 2022 first quarter results announcement, the company's revenue in the first quarter of 2022 was about 935 million yuan, a year-on-year increase of 22.
11%; net profit was about 237 million yuan, a year-on-year increase of 53.
09% ; Basic earnings per share was 0.
22 yuan, a year-on-year increase of 46.
67%
.
According to the data, the main business of Xinlitai’s subsidiaries involves the research and development, production and sales of drugs and medical device products.
The main products and research projects include cardiovascular drugs and medical devices, cephalosporin antibiotics and raw materials, orthopedic drugs, etc.
Covering cardiovascular and cerebrovascular, hypoglycemic, orthopedics, anti-tumor, anti-infection and other therapeutic fields
.
Shengxiang Bio: Net profit increased by 4.
78% year-on-year.
Shengxiang Bio's performance report for the first quarter of 2022 shows that from January 1, 2022 to March 31, 2022, the company achieved operating income of 1.
44 billion yuan, a year-on-year increase of 23.
81%; net profit; 652 million yuan, a year-on-year increase of 4.
78%; basic earnings per share were 1.
65 yuan
.
The company belongs to the medical device industry, and its main business is an overall solution for in vitro diagnostics that integrates the R&D, production, and sales of diagnostic reagents and instruments, as well as third-party medical testing services, with independent innovative genetic technology as the core
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
